TREATMENT OF HDV GENOTYPE 3 INFECTION WITH PEG-INTERFERON AND ENTECAVIR

Highlights • We evaluated the effects of therapy with PEG-IFN in patients with HDV-3 and correlated them with a possible cure rate higher than expected. • Therapeutic protocol used presents satisfactory response levels to orient the virologic response (VR)portion of the treated subjects. • HDV patients in the Amazon region can be treated with a combination of PEG-IFN alpha and Entecavir for 48 weeks, with good chances of Negative HDV RNA at week 24. • Our results suggest that HDV-3 in the native population may be an “easy to treat” variant compared to HDV-1.